- Sobre
- Acesso Aberto
- Quem somos
- Missão e objetivos
- Nossa história
- Quem participa
- Parceiros
- Documentação
- Contratos
- Acervo
- Buscar assunto
- Lista de bases e coleções
- Lista de livros
- Lista de periódicos
- Treinamentos
- Calendário
- Materiais de apoio
- Informativos
- Ajuda
- Perguntas frequentes
- Suporte regional
- Fale conosco
Você tem acesso ao conteúdo gratuito do Portal de Periódicos da CAPES
Acesso CAFe
Sua pesquisa será realizada no conteúdo gratuito disponível no acervo do Portal de Periódicos da CAPES. O conteúdo assinado com as editoras científicas está disponível para os IPs identificados das instituições participantes. Caso você esteja acessando fora da rede da sua instituição, é necessário efetuar o login na Comunidade Acadêmica Federada (CAFe).
Acesso CAFe
- Acervo
- Buscar assunto
'; html += '
'; html += '
'; html += '
'; // Adicione o HTML à div $('#cited-by').append(html); $('#cited-by-title').removeClass("d-none"); }); }) .fail(function(xhr, status, error) { console.error('Erro na chamada AJAX:', status, error); }); $(document).on("click", '.favorito', function() { let idItem = $(this).data('item'); let objeto = this; $(`#result-busca-load-${idItem}`).removeClass("d-none"); $(`#conteudo-${idItem}`).addClass("d-none"); let id = $(this).data('id'); let action = $(this).data('action'); let source = $(this).data('source'); $.ajax({ type: 'GET', dataType: 'json', url: `/index.php?option=com_pbuscador&task=favorite&id=${id}&action=${action}&source=${source}`, success: function(data) { $(`#result-busca-load-${idItem}`).addClass("d-none"); $(`#conteudo-${idItem}`).removeClass("d-none"); if(data.code != 'error'){ $(objeto).toggleClass('fa far'); } renderMessages({ message: data.response, type: data.code, title: 'Meus Favoritos' }); }, error: function(data) { $(`#result-busca-load-${idItem}`).addClass("d-none"); $(`#conteudo-${idItem}`).removeClass("d-none"); renderMessages({ message: data.response, type: data.code, title: 'Meus Favoritos' }); } }); }) function renderMessages(data){ var backgroundColor = ''; if(data.type == 'error'){ backgroundColor = '#ff0000'; } var toastHtml = `
${data.title}
${data.message}
`; document.body.insertAdjacentHTML('beforeend', toastHtml); $('.toast').toast('show'); } $('#btnCopyLink').click(function () { new ClipboardJS('#btnCopyLink'); alert('URL copiada com sucesso!'); }); $('#exportBibTex').click(function () { let content = generateBibTeX(); downloadTxtFile(content, 'Periodicos-CAPES-BibTex', 'bib'); }); $('#exportRIS').click(function () { let content = generateRIS(); downloadTxtFile(content, 'Periodicos-CAPES-RIS', 'ris'); }); function downloadTxtFile(content, tipo, ext) { const blob = new Blob([content], { type: "text/plain" }); const anchor = document.createElement("a"); anchor.href = window.URL.createObjectURL(blob); anchor.download = `${tipo}.${ext}`; document.body.appendChild(anchor); anchor.click(); document.body.removeChild(anchor); }; // Função para gerar formato BibTeX function generateBibTeX() { return `@Artigo{W3002978961, title={Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer}, author={Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo, Toru Kumagai, Ryohei Katayama, Makoto Nishio, Mei-mei Zheng, Yi‐Long Wu, Hiroshi Nishihara, Takushi Yamamoto, Mitsutoshi Nakada, Seiji Yano}, journal={Miscellaneous}, year={2020}, volume={15}, number={5}, pages={752}-{765}, doi={10.1016/j.jtho.2020.01.001}, keywords={} }`; } // Função para gerar formato RIS function generateRIS() { return `TY - Artigo ID - W3002978961 TI - Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer AU - Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo, Toru Kumagai, Ryohei Katayama, Makoto Nishio, Mei-mei Zheng, Yi‐Long Wu, Hiroshi Nishihara, Takushi Yamamoto, Mitsutoshi Nakada, Seiji Yano PY - 2020 JO - Miscellaneous VL - 15 IS - 5 SP - 752 EP - 765 DO - 10.1016/j.jtho.2020.01.001 ER -`; } function imprimirDiv() { setTimeout(function() { var conteudoOriginal = document.body.innerHTML; var conteudoDiv = document.getElementById("content-print").innerHTML; document.body.innerHTML = conteudoDiv; window.print(); document.body.innerHTML = conteudoOriginal; }, 2000); }});
Publicação - Artigo Revisado por pares Acesso aberto
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer
2020; Elsevier BV; Volume: 15; Issue: 5 Linguagem: Inglês
10.1016/j.jtho.2020.01.001
ISSN
1556-1380
Autores
Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo, Toru Kumagai, Ryohei Katayama, Makoto Nishio, Mei-mei Zheng, Yi‐Long Wu, Hiroshi Nishihara, Takushi Yamamoto, Mitsutoshi Nakada, Seiji Yano
Tópico(s)
Small Cell Lung Cancer
Resumo
IntroductionLeptomeningeal carcinomatosis (LMC) occurs frequently in anaplastic lymphoma kinase (ALK)–rearranged NSCLC and develops acquired resistance to ALK tyrosine kinase inhibitors (ALK TKIs). This study aimed to clarify the resistance mechanism to alectinib, a second-generation ALK TKI, in LMC and test a novel therapeutic strategy.MethodsWe induced alectinib resistance in an LMC mouse model with ALK-rearranged NSCLC cell line, A925LPE3, by continuous oral alectinib treatment, established A925L/AR cells. Resistance mechanisms were analyzed using several assays, including Western blot and receptor tyrosine kinase array. We also measured amphiregulin (AREG) concentrations in cerebrospinal fluid from patients with ALK-rearranged NSCLC with alectinib-refractory LMC by enzyme-linked immunosorbent assay.ResultsA925L/AR cells were moderately resistant to various ALK TKIs, such as alectinib, crizotinib, ceritinib, and lorlatinib, compared with parental cells in vitro. A925L/AR cells acquired the resistance by EGFR activation resulting from AREG overexpression caused by decreased expression of microRNA-449a. EGFR TKIs and anti-EGFR antibody resensitized A925L/AR cells to alectinib in vitro. In the LMC model with A925L/AR cells, combined treatment with alectinib and EGFR TKIs, such as erlotinib and osimertinib, successfully controlled progression of LMC. Mass spectrometry imaging showed accumulation of the EGFR TKIs in the tumor lesions. Moreover, notably higher AREG levels were detected in cerebrospinal fluid of patients with alectinib-resistant ALK-rearranged NSCLC with LMC (n = 4), compared with patients with EGFR-mutated NSCLC with EGFR TKI–resistant LMC (n = 30), or patients without LMC (n = 24).ConclusionsThese findings indicate the potential of novel therapies targeting both ALK and EGFR for the treatment of ALK TKI–resistant LMC in ALK-rearranged NSCLC.
Referência(s)
Exportar
Publicação - Artigo Revisado por pares Acesso aberto
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer
2020; Elsevier BV; Volume: 15; Issue: 5 Linguagem: Inglês
Usamos cookies para fornecer uma melhor experiência ao usuário no acesso ao Portal de Periódicos da CAPES, conforme nossa política e, ao continuar navegando, você concorda com essas condições. Entendi